Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600537 | 0.93 | P2RY12 (0.61) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4737004 | 0.91 | P2RY12 (0.75) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL5012431 | 0.87 | P2RY12 (0.54) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3590489 | 0.87 | P2RY12 (0.82) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4785763 | 0.87 | P2RY12 (0.70) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4872404 | 0.86 | P2RY12 (0.71) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3596659 | 0.85 | P2RY12 (0.81) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4872898 | 0.84 | P2RY12 (0.79) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3592970 | 0.84 | ALDH1A1 (0.67) | P2RY12ALDH1A1KDM4ENPSR1 | |
| SCHEMBL4736388 | 0.83 | P2RY12 (0.73) | P2RY12CYP3A4CYP2C9CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | claimed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | claimed |
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039437-A1 | New Pyridine Analogues III | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885CYP3A4 202/4885CYP2C9 331/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 728/4885CYP2C9 873/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 140/4885CYP2C9 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.